title: [Use of a Transtec transdermal therapeutic system of buprenorphine for analgesia in the early periods after cardiosurgical operations].
abstract: The analgesic effect of a transdermal therapeutic system (TTS) (Transtec) of buprenorphine was evaluated for analgesia in cardiosurgical patients in the early postoperative period. Before sternotomy, Transtec was applied to the skin of the shoulder in 30 patients operated on the heart under extracorporeal circulation. A control group comprised 20 patients receiving the nonsteroidal anti-inflammatory agent Xifocam in an intravenous dose of 8 mg twice daily. The first injection of Xefocam was made 1.5-2 hours prior to tracheal extubation. With the use of Transtec, the degree of pain was 1.58 scores by the five-score scale at the moment of tracheal extubation; it reduced to 1 score 16 hours after extrubation; it was 0.76 scores by the end of the first day, less than 0.5 score by the middle of day 2, reduced to zero by the end of day 3. By the moment of tracheal extubation, the degree of pain in patients receiving Xefocam was 3 scores; by the end of 24 hours, it reduced to 2 scores and remained the same by the end of day 3. During more effective analgesia with Transtec, inspiratory lung capacity was much higher than during that with Xefocam. The difference in the mean values of this parameter was 510 to 830 ml (p < 0.05) at the stages of the investigation. The findings confirmed a rather long (72-hour) continuous and steady analgesic effect of Transtec TTS. Due to the analgesic effect of Transtec, there was a significant improvement of respiratory function in patients after cardiothoracic operations.
authors.forename: A A
authors.initials: AA
authors.lastname: Eremenko
authors.forename: A V
authors.initials: AV
authors.lastname: Urbanov
authors.forename: M I
authors.initials: MI
authors.lastname: Avetisian
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000698:Analgesia / Q000295:instrumentation*; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D002047:Buprenorphine / Q000008:administration & dosage* / Q000009:adverse effects; D006348:Cardiac Surgical Procedures; D016022:Case-Control Studies; D005112:Extracorporeal Circulation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000517:prevention & control*; D010147:Pain Measurement; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives; D011182:Postoperative Care
chemical_list: D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; D002047:Buprenorphine; C059451:lornoxicam